Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces stress-induced neuroplasticity, which plays a critical role in almost all mental disorders. The problem is conventional drugs have done little to correct damage in this response, resulting in mental health disorders that now affect nearly one in every eight people on the planet. Amazingly, research with psychedelic therapeutics has shown great promise, inspiring hope in treating a broad range of mental health disorders. With the urgent need for new, more effective treatments to treat a wide spectrum of disorders, Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) (Profile) is pioneering groundbreaking research and striking important partnerships to unleash the power of these psychedelic-based compounds. Cybin has a differentiated method of progressing psychedelics into therapeutics than others in the sector, such as COMPASS Pathways Plc (NASDAQ: CMPS), Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED), ATAI Life Sciences N.V. (NASDAQ: ATAI) and GH Research PLC (NASDAQ: GHRS), which are also intent on offering effective solutions. Cybin is looking to lead the psychedelic renaissance that could for the first time deliver treatments to address the root of mental maladies rather than just mask the symptoms with conventional drugs.
To hear the NetworkNewsAudio version, visit https://nnw.fm/JvwLe
To view the full editorial, visit https://nnw.fm/yWeyo
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
NetworkNewsAudio, a service of NetworkNewsWire (NNW), allows you to sit back and listen to market updates, interviews and company press releases. NetworkNewsAudio keeps you informed on publicly traded companies we’re watching. The audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio is a Brand Awareness Distribution Solution from NetworkNewsWire.
For more information, visit www.NetworkNewsAudio.com
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.